title: Codon 54 polymorphism of the fatty acid binding protein (FABP) 2 gene is associated with increased cardiovascular risk in the dyslipidemic diabetic participants of the Veterans Affairs HDL intervention trial (VA-HIT).
abstract: The threonine (Thr) for alanine (Ala) codon 54 polymorphism of the fatty acid binding protein (FABP) 2 gene, when compared to the wild type, is associated with dyslipidemia. Since dyslipidemia is common in diabetes and is associated with increased cardiovascular risk, we tested the hypothesis that Thr-54 is associated with increased cardiovascular risk in patients with diabetes. The secondary prevention veterans affairs HDL intervention trial (VA-HIT) was carried out in patients with dyslipidemia. The DNA of trial participants (n=776) was screened for the Thr-54 polymorphism and cardiovascular endpoints were monitored. The polymorphism was detected in 370 (47.7%). For first occurrence of the primary endpoint [myocardial infarction (MI) or coronary heart disease (CHD) death] the hazard ratio (HR) and confidence intervals (Cox proportional hazards model) was 2.5 (1.2, 5.3) p=.02 in diabetic carriers of Thr-54 versus carriers without diabetes or fasting glucose >7 mmol/L. For the expanded endpoint (stroke, MI or CHD death), the corresponding HR was 3.0 (1.4, 5.4) p=.0003 and for the stroke alone the corresponding HR was 3.5 (1.4-8.9) p=.01. The higher cumulative incidence of the expanded endpoint in diabetic participants carrying the FABP2 polymorphism versus non-diabetic carriers was consistently present throughout the 5 years of the study (p=.0002). We conclude that based on the VA-HIT data, the Thr-54 polymorphism of the FABP2 gene is associated with a 2-3.5-fold increase in cardiovascular risk in dyslipidemic men with diabetes compared to their non-diabetic counterparts.
authors.affiliation: Medicine Service, Veterans Affairs Medical Center, Minneapolis, MN, USA. georg003@umn.edu
authors.forename: Angeliki
authors.initials: A
authors.lastname: Georgopoulos
authors.forename: Hanna
authors.initials: H
authors.lastname: Bloomfield
authors.forename: Dorothea
authors.initials: D
authors.lastname: Collins
authors.forename: Margaret E
authors.initials: ME
authors.lastname: Brousseau
authors.forename: Jose M
authors.initials: JM
authors.lastname: Ordovas
authors.forename: John J
authors.initials: JJ
authors.lastname: O'Connor
authors.forename: Sander J
authors.initials: SJ
authors.lastname: Robins
authors.forename: Ernest J
authors.initials: EJ
authors.lastname: Schaefer
mesh_terms: D000368:Aged; D003062:Codon / Q000235:genetics; D003920:Diabetes Mellitus / Q000453:epidemiology / Q000235:genetics*; D050171:Dyslipidemias / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics*; D050556:Fatty Acid-Binding Proteins / Q000235:genetics*; D015248:Gemfibrozil / Q000627:therapeutic use; D020022:Genetic Predisposition to Disease / Q000453:epidemiology; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D015994:Incidence; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology / Q000235:genetics*; D011110:Polymorphism, Genetic; D012307:Risk Factors; D020521:Stroke / Q000453:epidemiology / Q000235:genetics*; D014481:United States; D014493:United States Department of Veterans Affairs
chemical_list: D003062:Codon; C493404:FABP2 protein, human; D050556:Fatty Acid-Binding Proteins; D000960:Hypolipidemic Agents; D015248:Gemfibrozil